Late-Stage CNS Drugs Key For Alkermes, But Early-Stage IL-2 Agonist Fascinates

Immuno-oncology R&D based around an interleukin-2 agonist in early clinical studies has attracted attention to Alkermes, but the CNS disorders specialty company is also concentrating on a new mechanism-of-action antidepressant that is nearing the market, and a new antipsychotic.